"This acquisition creates the world's premier cancer diagnostics company
focused on dermatopathology, anatomic pathology and molecular diagnostics,"
said Surya N. Mohapatra, Ph.D., Chairman and Chief Executive Officer of Quest
Diagnostics. "This combination will accelerate growth, while providing
compelling benefits for patients, physicians, hospitals and payers."
About Quest Diagnostics
Quest Diagnostics is the leading provider of diagnostic testing,
information and services that patients and doctors need to make better
healthcare decisions. The company offers the broadest access to diagnostic
testing services through its national network of laboratories and patient
service centers, and provides interpretive consultation through its extensive
medical and scientific staff. Quest Diagnostics is a pioneer in developing
innovative new diagnostic tests and advanced healthcare information technology
solutions that help improve patient care. Additional company information is
available at: www.questdiagnostics.com.
This communication contains certain forward-looking statements. These
forward-looking statements, which may include, but are not limited to,
statements concerning the proposed acquisition, are based on management's
current expectations and estimates and involve risks and uncertainties that
could cause actual results or outcomes to differ materially from those
contemplated by the forward-looking statements. Certain of these risks and
uncertainties may include, but are not limited to the risks and uncertainties
described in the Quest Diagnostics Incorporated 2006 Form 10-K and subsequent
filings.
SOURCE Quest Diagnostics
media, Nancy Fitzsimmons, +1-201-393-5700, or investors, Laure Park, +1-201-393-5030,
both of Quest Diagnostics
http://www.questdiagnostics.com